In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.
In season 2, episode 8 of “Targeted Talks,” Thomas Hutson, DO, PharmD, of Texas Oncology, a part of the US Oncology Network, and Rana R. McKay, MD, of UC San Diego Health, discuss the renal cell carcinoma (RCC) paradigm and challenges to overcome in the future.
Kidney cancer has experienced multiple paradigm shifts, according to Hutson. Most recently, second-generation drugs like immune checkpoint inhibitors have become a backbone therapy in the frontline setting. McKay explains that these drugs are now being used successfully in combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy). Also, immunotherapy and VEGF inhibitor combination like pembrolizumab (Keytruda) plus axitinib (Inlyta) and avelumab (Bavencio) plus axitinib are being newly introduced in clinical practice. The newest doublets include nivolumab in combination with cabozantinib (Cabometyx) and lenvatinib (Lenvima) in combination with pembrolizumab.
The next step for providing optimal treatment to patients with RCC may be bringing these ICIs into the adjuvant setting, both physicians stated. Further, with the influx of new therapies and even more novel treatment in the development phase, understanding how to sequence these therapies remains an important clinical question. Another important unmet need in research space is identifying new targets in RCC.
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More